Please use this identifier to cite or link to this item:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE|
What is the impact of the antibody response to glycan Alpha-Gal in Guillain-Barré syndrome associated with SARS-CoV-2 infection?
|Authors:||Doncel-Pérez, Ernesto CSIC ORCID; Contreras, Marinela; Gómez Hernando, Cesar; Vargas Baquero, Eduardo; Blanco García, Javier; Rodríguez Gómez, Javier; Velayos Galán, Alberto; Cabezas-Cruz, Alejandro; Gortázar, Christian CSIC ORCID; Fuente, José de la CSIC ORCID||Issue Date:||2020||Publisher:||Merit Research Journals||Citation:||Merit Research Journal of Medicine and Medical Sciences 8(11): 730-737 (2020)||Abstract:||There are several reports of the onset of Guillain-Barré syndrome (GBS) symptoms in COVID-19 patients. Previously, we reported that reduction in anti-α-Gal IgE, IgM and IgG antibody titers and alteration of anti-α-Gal antibody isotype composition correlated with COVID-19 severity. In this case study, we aimed to compare the anti-α-Gal antibody response in COVID-19 and GBS patients. The levels of anti-α-Gal IgE, IgM, IgG and IgA were measured by ELISA in the sera of GBS and COVID-19 patients. Patients diagnosed with GBS showed an increase in anti-α-Gal IgM when compared to healthy individuals and COVID-19 patients. The levels of anti-α-Gal IgA were significantly higher in COVID-19 patients. No significant differences were observed in the levels of IgE and IgG between GBS and COVID-19 patients. Profile of anti-α-Gal antibody isotypes revealed a higher representation of anti-α-Gal IgM and IgG among GBS and COVID-19 patients, respectively. Remarkably, anti-α-Gal IgM was also highly represented in SARS-CoV-2 positive patients suffering GBS. Despite the limited number of cases included in the study, we suggest that anti-α-Gal IgM and IgA responses are differentially regulated in GBS and COVID-19 patients, which could reflect the disparate etiologies of these diseases. A possible association between high anti-α-Gal IgA in GBS and COVID-19 severity is proposed.||URI:||http://hdl.handle.net/10261/230769||ISSN:||2354-323X|
|Appears in Collections:||(VICYT) Colección Especial COVID-19|
Show full item record
Review this work
checked on Jul 5, 2022
checked on Jul 5, 2022
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.